Q3 sales fell 10.6%, but margins improved. MRO capacity expansion is expected to bolster EBITDA by $50 million annually.

Rocket Lab (NASDAQ:RKLB) just reported its Q3 results, and the stock is up around 20%. In fact, RKLB is up over 100% in the ...

TME's Q3 2024 results show revenue and profit growth, but a sequential slowdown in growth rate, leading to a 5.45% stock drop ...

Altimmune, Inc.’s Pemvidutide shows promise as a dual-action treatment for obesity and MASLD/MASH, targeting weight loss, ...